The nation of Zimbabwe has declined a significant American health deal worth $367m (272 million pounds) over five years over the United States' insistence on sensitive data.
The decision became public after a official document from December was leaked, indicating that President Emmerson Mnangagwa believed the deal was "unbalanced".
An official spokesman later explained that the US was requesting biological samples for research and commercial gain but was unwilling to share the benefits from any future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more talks to find a agreement acceptable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Context
This development comes after a comparable case in Kenya, where a high court halted a related deal with the US after legal challenges were raised about the security of Kenyans' medical information.
After returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral deals to boost transparency and accountability.
According to reports, Sixteen nations in Africa have so far agreed to these new agreements, constituting more than $18.3bn in committed funds.
Specifics of the Declined Agreement
The money for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million currently receiving antiretroviral therapy via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, with no corresponding promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Effectively, our country would supply the raw materials for scientific discovery without any assurance that the final treatments would be available to our people if a new health crisis emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting systems already established through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to manage potential pandemics.
"This mechanism is designed to guarantee that when a country provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," he added.
"We encourage continued dialogue with our American counterparts on how future co-operation might be arranged in a manner that respects the independence and dignity of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but urged that talks must proceed considering a large portion of the nation's Aids initiatives were funded by external financing.
"If specific concerns arise, including those relating to data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group added.
This impasse highlights the ongoing tensions between receiving vital foreign assistance and safeguarding local interests in an ever more data-driven world.